/MBRX
MBRX Stock - Moleculin Biotech, Inc.
Healthcare|BiotechnologyNASDAQ
$3.90+1.83%
+$0.07 (+1.83%) • Dec 19
46
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $4.29
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MBRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.86 – $3.94
TARGET (TP)$4.48
STOP LOSS$3.59
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.58
52W High$91.25
52W Low$3.63
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-26,641,000 | $-29,631,000 | $-30,640,000 | $-22,968,000 | $-19,742,000 |
| Net Income | $-21,763,000 | $-29,769,000 | $-29,025,000 | $-15,894,000 | $-17,355,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-158.00 | $-376.75 | $-380.50 | $-221.75 | $-661.00 |
Company Overview
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$9
Average Target
↑ 130.8% Upside
Now
$4
Low
$9
Average
$14
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 9th 2025 | H.C. Wainwright | Resumed | Buy | $4 |
| February 12th 2025 | Maxim Group | Downgrade | Hold | - |
| July 18th 2022 | Oppenheimer | Resumed | Outperform | $14 |
Earnings History & Surprises
MBRXBeat Rate
61%
Last 18 quarters
Avg Surprise
+6.2%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$-3.25
Q4 2025
EPS Surprise History
Q1 24
-64.6%
$-5.02vs$-3.05
Q2 24
+43.7%
$-2.02vs$-3.59
Q3 24
-6.2%
$-2.23vs$-2.10
Q4 24
-16.8%
$-2.85vs$-2.44
Q1 25
+76.0%
$-0.37vs$-1.54
Q2 25
+2.8%
$-0.69vs$-0.71
Q3 25
-25.6%
$-0.49vs$-0.39
Q4 25
+35.0%
$-3.25vs$-5.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 20, 2026 | $-7.97 | — | — | — |
Q1 2026 | Mar 19, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-5.00 | $-3.25 | +35.0% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.39 | $-0.49 | -25.6% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.71 | $-0.69 | +2.8% | ✓ BEAT |
Q1 2025 | Mar 21, 2025 | $-1.54 | $-0.37 | +76.0% | ✓ BEAT |
Q4 2024 | Nov 11, 2024 | $-2.44 | $-2.85 | -16.8% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-2.10 | $-2.23 | -6.2% | ✗ MISS |
Q2 2024 | May 10, 2024 | $-3.59 | $-2.02 | +43.7% | ✓ BEAT |
Q1 2024 | Mar 22, 2024 | $-3.05 | $-5.02 | -64.6% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-3.15 | $-2.85 | +9.5% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-4.20 | $-3.00 | +28.6% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-3.75 | $-4.20 | -12.0% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-4.20 | $-3.60 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-4.05 | $-4.50 | -11.1% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-3.75 | $-3.60 | +4.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-3.15 | $-3.60 | -14.3% | ✗ MISS |
Q1 2022 | Mar 25, 2022 | $-3.15 | $-2.55 | +19.0% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $-3.00 | $-2.25 | +25.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-3.00 | $-2.85 | +5.0% | ✓ BEAT |
Latest News
Moleculin Biotech Data From Phase Clinical Study Of WP1066 Demonstrates Anti-Tumor Immune Responses To Treat Pediatric Recurrent Malignant Brain Tumors
📈 PositiveBenzinga•Dec 17, 2025, 01:35 PM
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22
📈 PositiveBenzinga•Dec 11, 2025, 11:33 AM
Moleculin Biotech shares are trading lower after the company announced an exercise of warrants for $6.8 million gross proceeds.
➖ NeutralBenzinga•Dec 10, 2025, 02:10 PM
Moleculin announces exercise of warrants for $6.8M
📈 PositiveSeeking Alpha•Dec 10, 2025, 02:07 PM
Moleculin Biotech Announces Immediate Exercise Of Warrants Covering 727,969 Shares At $6.63 And 316,360 Shares At $6.3219, Generating ~$6.5M Gross Proceeds Before Fees
📈 PositiveBenzinga•Dec 10, 2025, 01:35 PM
Moleculin Biotech Raises $6.5M From Immediate Exercise Of 1,044,329 Warrants At $6.63 And $6.3219, Issues 2.61M New Warrants At $6.63
📈 PositiveBenzinga•Dec 10, 2025, 01:34 PM
Moleculin Biotech Reports 78% Enrollment Toward First Interim Data Unblinding In Pivotal Phase 2B/3 MIRACLE Study Of Annamycin + Cytarabine In r/r AML
📈 PositiveBenzinga•Dec 9, 2025, 01:15 PM
Moleculin Biotech Partners With CIC biomaGUNE To Preclinically Test Annamycin For Glioblastoma Treatment
📈 PositiveBenzinga•Dec 8, 2025, 01:21 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 1, 2025, 01:55 PM
Moleculin Biotech shares are trading lower after the company announced a 1-for-25 reverse stock split.
📉 NegativeBenzinga•Nov 26, 2025, 07:56 PM
Moleculin to execute 1-for-25 reverse stock split
➖ NeutralSeeking Alpha•Nov 26, 2025, 02:06 PM
Moleculin Announces 1-For-25 Reverse Stock Split, Effective December 1
📉 NegativeBenzinga•Nov 26, 2025, 02:01 PM
Moleculin Reports 60% of First 45 Subjects In Pivotal "MIRACLE" Phase 3 AML Trial Consented
📈 PositiveBenzinga•Nov 13, 2025, 01:39 PM
Moleculin Announced Grant Funded Research Evaluating Annamycin To Treat Pancreatic Cancer at UNC-Chapel Hill
📈 PositiveBenzinga•Nov 12, 2025, 01:39 PM
Moleculin Biotech To Present Updates On Its Ongoing Phase 3 MIRACLE Clinical Trial For Acute Myeloid Leukemia At 14th Annual Acute Leukemia Meeting
➖ NeutralBenzinga•Oct 30, 2025, 12:42 PM
Moleculin Secures Australian Patent For Preliposomal Annamycin Lyophilizate With Enhanced Stability
📈 PositiveBenzinga•Oct 29, 2025, 12:38 PM
Moleculin Biotech Enters Collaboration With Atlantic Health On An Investigator-Initiated Phase 1B/2 Study To Evaluate Its Drug Candidate Annamycin As A Third-Line Treatment For Advanced Pancreatic Cancer
📈 PositiveBenzinga•Oct 23, 2025, 12:05 PM
Moleculin Biotech Secures Canadian Patent Titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE"
📈 PositiveBenzinga•Sep 25, 2025, 12:40 PM
Moleculin Biotech Files Prospectus For Resale, From Time To Time, By Selling Stockholders Of Up To 64.9M Shares Of Common Stock
➖ NeutralBenzinga•Sep 19, 2025, 09:21 PM
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $4 Price Target
📈 PositiveBenzinga•Sep 10, 2025, 10:52 AM
Frequently Asked Questions about MBRX
What is MBRX's current stock price?
Moleculin Biotech, Inc. (MBRX) is currently trading at $3.90 per share. The stock has moved +1.83% today.
What is the analyst price target for MBRX?
No analyst price targets are currently available for this stock.
What sector is Moleculin Biotech, Inc. in?
Moleculin Biotech, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MBRX's market cap?
Moleculin Biotech, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does MBRX pay dividends?
No, Moleculin Biotech, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
AIMD
Ainos, Inc.
$2.11
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
BLRX
BioLineRx Ltd.
$3.04
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
THAR
Tharimmune, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to MBRX for comparison